A healthcare firm described as at the forefront of next-generation therapeutic ultrasound systems, Acoustiic, Inc., management announced closing a funding round and expanding its team and facilities to develop non-invasive, early treatment of multiple diseases. The firm is creating an ultrasound tech platform for the treatment of a wide variety of potential clinical indications in a compact, modular, and versatile system to further improve patient outcomes and lowering costs. For treatment of one of the indications, liver and pancreatic cancer, Acoustiic has received Breakthrough Device Designation from the US Food and Drug Administration with funding ysed to accelerate the companys production of its first-generation therapy system, while continuing development of next-generation systems for wider indication application
